No news is bad news for Tocagen

No news is bad news for Tocagen

Source: 
BioPharma Dive
snippet: 

Tocagen said Tuesday its brain cancer trial has not been able to show so far that a combination therapy of experimental agents Toca 511 and Toca FC extended survival when compared with chemotherapy or Avastin. The announcement was based on an interim analysis and the study will proceed to a final readout later this year.